Suggested remit - To appraise the clinical and cost effectiveness of galcanezumab within its marketing authorisation for preventing cluster headache.
Following on from information provided to NICE by the company in April 2020 the appraisal of Galcanezumab for preventing episodic cluster headache [ID1212] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1212
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Note added to the project documents |
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in April 2020 the appraisal of Galcanezumab for preventing episodic cluster headache [ID1212] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 24 February 2021 | Expected publication |
| 17 April 2020 | Note added to the project documents |
| 17 April 2020 | Suspended. Topic is suspended |
| 12 December 2019 | In progress. Referred: April 29 2019 |
| 12 December 2019 | Note added to the project documents |
| 13 November 2018 - 11 December 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual